Vaxcyte (PCVX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Vaxcyte (PCVX)
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.
Key Insights
Critical company metrics and information
Share Price
$92.32Market Cap
$11.51 BillionTotal Outstanding Shares
124.64 Million SharesTotal Employees
254Dividend
No dividendIPO Date
June 12, 2020SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.vaxcyte.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Exchange Gains/Losses | $-8.61 Million |
Net Cash Flow From Investing Activities, Continuing | $-1.46 Billion |
Net Cash Flow From Operating Activities | $-470.04 Million |
Net Cash Flow, Continuing | $513.88 Million |
Net Cash Flow From Investing Activities | $-1.46 Billion |
Net Cash Flow From Financing Activities, Continuing | $2.45 Billion |
Net Cash Flow From Financing Activities | $2.45 Billion |
Net Cash Flow | $505.27 Million |
Net Cash Flow From Operating Activities, Continuing | $-470.04 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Research and Development | $447.18 Million |
Net Income/Loss | $-507.65 Million |
Diluted Earnings Per Share | $-4.60 |
Basic Earnings Per Share | $-4.60 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Diluted Average Shares | $119.39 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Depreciation and Amortization | $5.00 Million |
Revenues | $0.00 |
Income/Loss From Continuing Operations Before Tax | $-507.65 Million |
Operating Expenses | $604.05 Million |
Other Operating Expenses | $151.77 Million |
Operating Income/Loss | $-604.05 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Net Income/Loss Available To Common Stockholders, Basic | $-507.65 Million |
Net Income/Loss Attributable To Parent | $-507.65 Million |
Basic Average Shares | $119.39 Million |
Income/Loss From Continuing Operations After Tax | $-507.65 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Other Non-current Assets | $1.18 Billion |
Liabilities | $142.11 Million |
Noncurrent Assets | $1.35 Billion |
Equity Attributable To Noncontrolling Interest | $0.00 |
Equity | $3.42 Billion |
Other Current Liabilities | $93.33 Million |
Accounts Payable | $18.22 Million |
Non-current Prepaid Expenses | $284,000.00 |
Prepaid Expenses | $10.59 Million |
Current Assets | $2.21 Billion |
Assets | $3.56 Billion |
Equity Attributable To Parent | $3.42 Billion |
Noncurrent Liabilities | $18.32 Million |
Current Liabilities | $123.79 Million |
Fixed Assets | $163.24 Million |
Wages | $12.24 Million |
Other Current Assets | $2.20 Billion |
Liabilities And Equity | $3.56 Billion |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.